Delayed
Hong Kong S.E.
04:08:20 2024-05-14 am EDT
|
5-day change
|
1st Jan Change
|
25.6
HKD
|
+1.59%
|
|
+6.44%
|
+22.49%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
16,708
|
8,413
|
4,747
|
6,088
|
7,580
|
-
|
-
|
Enterprise Value (EV)
1 |
12,248
|
5,924
|
4,367
|
6,088
|
6,680
|
7,244
|
7,604
|
P/E ratio
|
-0.86
x
|
-8.24
x
|
-18.5
x
|
-
|
-11.6
x
|
-47.1
x
|
474
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
155,805
x
|
371
x
|
48.3
x
|
11.2
x
|
5.05
x
|
3.27
x
|
EV / Revenue
|
-
|
109,710
x
|
341
x
|
48.3
x
|
9.87
x
|
4.83
x
|
3.28
x
|
EV / EBITDA
|
-18.3
x
|
-5.95
x
|
-20.4
x
|
-
|
-14.2
x
|
63.8
x
|
26.1
x
|
EV / FCF
|
-12.8
x
|
-7.32
x
|
-
|
-
|
-5.5
x
|
-22.9
x
|
-33.2
x
|
FCF Yield
|
-7.81%
|
-13.7%
|
-
|
-
|
-18.2%
|
-4.38%
|
-3.01%
|
Price to Book
|
0.71
x
|
1.41
x
|
0.81
x
|
-
|
1.84
x
|
2.01
x
|
1.88
x
|
Nbr of stocks (in thousands)
|
293,222
|
296,715
|
309,246
|
320,493
|
319,835
|
-
|
-
|
Reference price
2 |
56.98
|
28.36
|
15.35
|
19.00
|
23.70
|
23.70
|
23.70
|
Announcement Date
|
3/22/21
|
3/28/22
|
3/30/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
0.054
|
12.8
|
125.9
|
676.5
|
1,501
|
2,320
|
EBITDA
1 |
-
|
-668.1
|
-995.2
|
-214
|
-
|
-469
|
113.5
|
291.6
|
EBIT
1 |
-
|
-688.5
|
-1,054
|
-256.8
|
-932.7
|
-672.8
|
-161.9
|
-96.4
|
Operating Margin
|
-
|
-
|
-1,952,274.07%
|
-2,006.25%
|
-740.67%
|
-99.45%
|
-10.79%
|
-4.16%
|
Earnings before Tax (EBT)
1 |
-
|
-5,658
|
-1,009
|
-247.3
|
-844.5
|
-645.5
|
-101.2
|
18.82
|
Net income
1 |
-214.5
|
-5,658
|
-1,009
|
-247.3
|
-844.5
|
-645.5
|
-160.4
|
16
|
Net margin
|
-
|
-
|
-1,867,962.96%
|
-1,932.03%
|
-670.57%
|
-95.42%
|
-10.69%
|
0.69%
|
EPS
2 |
-41.04
|
-66.29
|
-3.440
|
-0.8300
|
-
|
-2.042
|
-0.5031
|
0.0500
|
Free Cash Flow
1 |
-
|
-956.4
|
-808.8
|
-
|
-
|
-1,214
|
-317
|
-229
|
FCF margin
|
-
|
-
|
-1,497,844.44%
|
-
|
-
|
-179.45%
|
-21.12%
|
-9.87%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/20/20
|
3/22/21
|
3/28/22
|
3/30/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S2
|
2021 S1
|
2021 S2
|
2022 S1
|
2022 S2
|
2023 S1
|
2024 S1
|
2024 S2
|
---|
Net sales
1 |
-
|
-
|
0.054
|
1.044
|
11.76
|
8.9
|
252.7
|
459.7
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-406.3
|
-653.9
|
-639.6
|
382.8
|
-
|
-340.1
|
-295.1
|
Operating Margin
|
-
|
-
|
-1,210,977.78%
|
-61,269.16%
|
3,256.63%
|
-
|
-134.57%
|
-64.19%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
420.8
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
420.7
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
3,578.96%
|
-
|
-
|
-
|
EPS
2 |
-
|
-1.310
|
-2.130
|
-2.260
|
1.430
|
-
|
-1.010
|
-0.8300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/22/21
|
8/30/21
|
3/28/22
|
8/24/22
|
3/30/23
|
8/24/23
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
24.4
|
Net Cash position
1 |
-
|
4,460
|
2,489
|
380
|
-
|
901
|
336
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.0836
x
|
Free Cash Flow
1 |
-
|
-956
|
-809
|
-
|
-
|
-1,214
|
-317
|
-229
|
ROE (net income / shareholders' equity)
|
-
|
-189%
|
-15.8%
|
-4.28%
|
-
|
-14.5%
|
-6.33%
|
1.28%
|
ROA (Net income/ Total Assets)
|
-
|
-118%
|
-14.3%
|
-3.73%
|
-
|
-16.5%
|
-6.7%
|
-
|
Assets
1 |
-
|
4,807
|
7,061
|
6,631
|
-
|
3,912
|
2,394
|
-
|
Book Value Per Share
2 |
-
|
80.20
|
20.10
|
19.00
|
-
|
12.90
|
11.80
|
12.60
|
Cash Flow per Share
2 |
-
|
-5.530
|
-2.490
|
-3.880
|
-
|
-2.660
|
-0.6100
|
-
|
Capex
1 |
-
|
485
|
79
|
356
|
-
|
450
|
200
|
200
|
Capex / Sales
|
-
|
-
|
146,277.78%
|
2,780.59%
|
-
|
66.52%
|
13.33%
|
8.62%
|
Announcement Date
|
9/20/20
|
3/22/21
|
3/28/22
|
3/30/23
|
3/27/24
|
-
|
-
|
-
|
Last Close Price
23.7
CNY Average target price
26.02
CNY Spread / Average Target +9.80% Consensus |
1st Jan change
|
Capi.
|
---|
| +22.49% | 1.03B | | -1.17% | 89.37B | | +2.76% | 40.65B | | -12.32% | 32.81B | | +52.41% | 25B | | -17.39% | 15.29B | | -42.45% | 11.61B | | -10.48% | 11.49B | | +6.14% | 8.98B | | -7.72% | 8.23B |
Biopharmaceuticals
|